Use of immune checkpoint inhibitors is increasing. Some patients with NSCLC treated with nivolumab develop a radiographic cryptogenic organizing pneumonia (COP) pattern of PD-1 inhibitor-related pneumonitis. Recognition of the radiographic pattern is needed for prompt diagnosis and management.
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A Critical Role of miR-144 in Diffuse Large B-cell Lymphoma Proliferation and Invasion
Haiying Wang, Aihong Wang, Zhenbo Hu, Xin Xu, Zhiqiang Liu, and Zhanju Wang BCL6 supports the growth of DLBCL. Expression of the microRNA miR-144 in DLBCL cells inversely correlated with BCL6 expression. miR-144 inhibited BCL6 expression, affecting DLBCL proliferation and invasiveness. Thus, miR-144 should be considered in approaches to this cancer. Dr. Puré's research focuses on the cellular and molecular basis of inflammation and fibrosis. She studies the basic mechanisms involved in these processes and the contribution of these processes to disease, with an emphasis on cancer in preclinical animal models. A major focus of her laboratory's work is to define the role of stromal cells, extracellular matrix (ECM), and matrix remodeling in cancer initiation, progression, and metastasis; and to develop novel therapeutic approaches that target the stromal compartment of tumors to use in combination with more conventional therapies that target malignant cells and antiangiogenic therapies.
Two pathways of focus in Dr. Puré's lab are (i) hyaluronan, a prominent provisional and tumor-associated matrix glycosaminoglycan, and the principle hyaluronan receptor, CD44; and (ii) the cell surface serine protease fibroblast activation protein and the role of this protease in remodeling of collagen-rich provisional and tumor-associated matrix. Her lab established that CD44 promotes atherosclerosis, and they have defined multiple mechanisms by which CD44 promotes inflammation by mediating leukocyte recruitment and leukocyte and mesenchymal cell activation and migration. Her group also established that CD44 is required for intratumoral migration of tumor antigenspecific T cells and optimal antitumor immunity.
Dr. Puré and her colleagues defined fibroblast activation protein, FAP, as a marker of stromal cells and a subset of M2-like macrophages associated with active matrix remodeling in settings of chronic inflammation, tissue fibrosis, and virtually all epithelial-derived solid tumors. They demonstrated that, in human breast cancer, FAP þ stromal cells exhibit subtype-specific gene expression profiles consistent with the coevolution of tumor cells and stromal cells in the tumor microenvironment. Using an adoptive immunotherapy approach to target tumor stromal cells for deletion, her research group has established that FAP þ stromal cells are required for the generation and maintenance of the desmoplastic response that characterizes many solid human tumors. Dr. Puré's lab established that disrupting tumor-associated matrix by targeting the stromal compartment at either the molecular or cellular level effectively inhibits tumor growth through both immune-dependent and immune-independent mechanisms as a function of tumor immunogenicity and degree of desmoplasia associated with various tumor types. A current focus of her research is to understand what is emerging as a critical role for ECM composition, organization, and biomechanical signaling in tumor initiation, progression and metastasis, chronic inflammation, and fibrosis.
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